Last reviewed · How we verify
Placebo via DISKUS
Placebo via DISKUS is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Control arm in clinical trials (not a therapeutic indication).
Placebo produces no pharmacological effect and serves as an inert control in clinical trials and research studies.
Placebo produces no pharmacological effect and serves as an inert control in clinical trials and research studies. Used for Control arm in clinical trials (not a therapeutic indication).
At a glance
| Generic name | Placebo via DISKUS |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is a pharmacologically inactive substance administered in the same formulation and route as an active drug. It relies on the placebo effect—the therapeutic benefit derived from patient expectation and the clinical context—rather than any direct molecular mechanism. In this case, it is delivered via the DISKUS dry powder inhaler device.
Approved indications
- Control arm in clinical trials (not a therapeutic indication)
Common side effects
Key clinical trials
- MGR001 / Advair Diskus Local Equivalence Study in Asthma (PHASE3)
- An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs. (PHASE2)
- Succinate Salt Version of GSK961081 for Healthy Volunteers (PHASE1)
- A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (PHASE2)
- An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (PHASE2)
- Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects (PHASE2)
- Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo via DISKUS CI brief — competitive landscape report
- Placebo via DISKUS updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Placebo via DISKUS
What is Placebo via DISKUS?
How does Placebo via DISKUS work?
What is Placebo via DISKUS used for?
Who makes Placebo via DISKUS?
What development phase is Placebo via DISKUS in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Indication: Drugs for Control arm in clinical trials (not a therapeutic indication)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing